Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxfendazole for Mild Parenchymal Brain Cysticercosis
NCT06565507Phase 3Not yet recruiting
- Sponsor
- Universidad Peruana Cayetano Heredia
- Start
- Dec 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of oxfendazole in neurocysticercosis (NCC), sponsored by Universidad Peruana Cayetano Heredia. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
oxfendazole
03
Conditions
neurocysticercosis (NCC)
Beyond the preview
Go deeper on NCT06565507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565507.